Dr. Guillermo E. Umpierrez, USA
Area of Specialty: Endocrinology, Diabetes and Metabolism
Dr. Umpierrez is professor of medicine in the division of endocrinology, metabolism at Emory University School of Medicine, and chief of diabetes and endocrinology at Grady Memorial Hospital
Dr. Umpierrez first joined the Emory University School of Medicine faculty in 1992 – 1997. He returned in 2003 to focus on diabetes and metabolic disorders. Dr. Umpierrez’s research interests include mechanisms for ß-cell dysfunction in minority populations with ketosis-prone type 2 diabetes, the effects of free fatty acids on insulin secretion and hypertension in obese patients, and the inpatient management of insulin in critical and non-critical patients. His research programs at Grady Hospital and Emory University are funded by the National Institutes of Health (NIH), American Diabetes Association (ADA), and American Heart Association (AHA).
In 2009, Dr. Umpierrez received “Outstanding Service Award for the Promotion of Endocrine Health of an Underserved Population” by the American Association of Clinical Endocrinologists (AACE). The Outstanding Service Award the Promotion of Endocrine Health of an Underserved Population is given to an individual for exceptional contributions to the care, health, and service to an underserved population via leadership, long-term commitment, vision, innovation, and impact/outcomes.
Dr. Umpierrez heads the Emory Latino Diabetes Education Program (ELDEP), the first nationally accredited all Spanish Diabetes education program dedicated to providing diabetes education and lifestyle intervention to Latinos in Georgia
Under his leadership, the ELDEP has received funding in the amount close to $500,000 from the Healthcare Georgia Foundation and the pharmaceutical industry to develop a culturally sensitive, community-based diabetes education program targeting Latinos in metro Atlanta and throughout the state of Georgia. Umpierrez spearheaded the development of a video produced by the ELDEP “Viva mas y major…con su diabetes bajo control!” live longer and better with your diabetes under control!
I am committed to the mission of Grady and feel both honored and humbled by the opportunity to help the indigent and inner city population. I am motivated every day to continue to serve and to develop mechanisms to assure quality diabetes care in this vulnerable patient population at high risk for diabetes complications.
Dr Kenneth Cusi,
M.D., F.A.C.P., F.A.C.E.
Professor and Chief, Endocrinology, Diabetes & Metabolism
University of Florida
Epidemiology, Insulin Action, Insulin Action\Insulin Resistance, Obesity, Obesity\Clinical Treatment
Dr. Cusi is board certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism. He completed his residency at the Center of Medical Education & Clinical Research (CEMIC) in Buenos Aires, Argentina, and a clinical fellowship at Baylor College of Medicine in Houston. Prior to joining the University of Florida, Dr. Cusi was a faculty member of over 15 years in the Diabetes Division at the University of Texas Health Science Center at San Antonio (UTHSCSA) and the Veterans Health Administration System in Texas; one of the leading diabetes programs in the country. He is a fellow of the American College of Physicians (ACP) and the American Association of Clinical Endocrinologists (AACE).
Dr. Cusi currently serves as Chief of the Adult Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida. He oversees all adult endocrinology/diabetes inpatient consult activities and outpatient clinics at UF, Shands and the VAMC with the mission to provide the highest level of clinical care. He serves as a mentor for all clinical and laboratory research efforts, as well as mentors faculty and fellows in the division to help UF Health take the next step in becoming an international leader in adult diabetes, metabolism, and obesity. His experience in diabetes prior to UF was in the department of medicine at the University of Texas Health Science Center at San Antonio for more than 15 years. Cusi is the principal investigator of various ongoing clinical translational research projects in obesity, Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
Dr. Cusi has found in screening studies that most obese patients with T2DM have a fatty liver (as many as four out of five). This poses considerable long-term health risks: dyslipidemia, cardiovascular disease and liver damage. He discovered in a pilot study that pioglitazone (Actos), a drug used in the treatment of T2DM, may reverse a fatty liver in patients with prediabetes or T2DM (Belfort et al, NEJM 2006). Most recently, Dr. Cusi’s laboratory completed the first long-term study (presented at the June 2013 American Diabetes Association annual meeting) that has confirmed and extended the original findings about the efficacy of pioglitazone in obese patients with T2DM and a fatty liver (Cusi et al, Diabetes, suppl 1, 2013).
Dr George Grunberger
Medical Doctor, F.A.C.P., F.A.C.E.
George Grunberger, received his B.A. (biochemistry) from Columbia College of Columbia University (New York City), M.D. from New York University School of Medicine (New York City), internal medicine training at Case Western Reserve University in Cleveland, Ohio and Endocrinology/Metabolism training in the Diabetes Branch at the National Institutes of Health in Bethesda, Maryland where he then stayed as senior investigator.
Between 1986 and 2002 he established and then directed the Comprehensive Diabetes Programs at both the Detroit Medical Center and Wayne State University School of Medicine. Early in his career, Dr. Grunberger saw the need for a comprehensive diabetes treatment facility where persons with diabetes could receive specialized care and address the many facets of their disease. The Grunberger Diabetes Institute, established in 2002, is the result of his vision.
Is the Immediate Past President of the American Association of Clinical Endocrinologists (AACE, the largest organization of clinical endocrinologists in the world) and Chancellor of the American College of Endocrinology.
- Clinical Professor in the Department of Internal Medicine and in the Center for Molecular Medicine and Genetics at the Wayne State University School of Medicine
- Professor of Internal Medicine at the Oakland University William Beaumont School of Medicine
- Visiting Professor of Medicine in the First Faculty of Medicine at Charles University, Prague (Czech Republic)
- Fellow of the American College of Physicians, and the American College of Endocrinology
- Past President of the Michigan Chapter of the American Association of Clinical Endocrinologists (2006-2011)
- Past national AACE Board of Directors member, from 2006 to 2012
- Elected by his peers for inclusion in the Best Doctors in America® every year between 2001 and 2015
- A staff physician at Beaumont Hospital, Royal Oak.
- A sought after speaker on all aspects of diabetes nationally and internationally
- An author of over 150 scientific and medical articles in peer-reviewed literature, in edition to reviews and book chapters
Dr Timothy Garvey
Dr Garvey is the Butterworth Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. He obtained his MD degree from St. Louis University, completed residency training in Internal Medicine at Barnes Hospital, Washington University, and was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. He subsequently held faculty posts at the University of California, San Diego School of Medicine (Assistant Professor), Indiana University School of Medicine (Associate and full Professor), and at the Medical University of South Carolina where he was Director of the Division of Endocrinology, and at UAB since 2004.
Dr. Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, Type 2 Diabetes, and obesity. His studies have involved the cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on metabolic research wards, and the genetic basis of diseases in Gullah-speaking African Americans and other national cohorts of diabetes patients. The Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance and has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins in human insulin resistance. He has identified gene families that contribute to insulin resistance in human muscle insulin using cDNA microarray, e.g., NR4A orphan nuclear receptors and the tribbles gene family, and has elucidated the role of adiponectin in cardiometabolic disease and mitochondrial proteomics to better define mitochondrial defects that impair substrate oxidation. He has contributed to the training of our next generation of clinicians, basic scientists, and physician scientists. Since 1987, his laboratory has been supported by the National Institutes of Health (NIDDK, NHLBI), the Department of Veterans Affairs, the AHA, JDFI, the ADA, and other agencies.
Dr. Garvey’s career has been distinguished by a second impactful sphere of activity. He has developed an intense interest in our understanding of obesity as a disease, and in advancing medical models to improve the care of patients with obesity. Dr. Garvey was the chief architect of the Complications-Centric Model for Care of the Overweight/Obese Patient. Much of his work in this area has occurred as a board member in the American Association of Clinical Endocrinologists and Chair of the AACE Obesity Scientific Committee (2012-present). Dr. Garvey was a leading contributor and author in the AACE Position Statement designating Obesity as a disease (Endocrine Practice 18:642, 2012); the AACE proposition voted by the AMA House of Delegates affirming Obesity as a disease in 2013; the obesity treatment algorithm in the AACE Comprehensive Diabetes Management Algorithms; Chair of the AACE Obesity Consensus Conference held in Washington DC on March 23-25, 2014; lead author on the evidence-based AACE obesity management guidelines (Endocr Pract. 22(7):842, 2016); and co-author of the new medical diagnostic term for obesity – Adiposity-Based Chronic Disease. This obesity treatment algorithm emphasizes the use of weight loss therapy to treat obesity-related complications as the primary goal of treatment, as opposed to reductions in BMI per se. Further, Dr. Garvey developed Cardiometabolic Disease Staging (Obesity 22:110, 2014) that allows clinicians to quantitatively assign risk for Type 2 Diabetes and cardiovascular disease mortality, when deciding upon the treatment modality and intensity of weight loss therapy for their patients, within the context of a complications-centric medical approach. This work is widely applicable and relevant to policy-making regarding the prevention of diabetes. Thus, Dr. Garvey is a national leader in the development of medical models for the management of obesity and diabetes prevention.